A Phase IIA study of the topoisomerase-1 inhibitor, exatecan mesylate (DX-8951f) administered at 2 different dose schedules in patients with platinum and taxane resistant/refractory ovarian cancer

GC Jayson

A Phase IIA study of the topoisomerase-1 inhibitor, exatecan mesylate (DX-8951f) administered at 2 different dose schedules in patients with platinum and taxane resistant/refractory ovarian cancer

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	114-119
Journal	Gyne. Oncol
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{262e6ec38dc948f1822945ea50238bce,

title = "A Phase IIA study of the topoisomerase-1 inhibitor, exatecan mesylate (DX-8951f) administered at 2 different dose schedules in patients with platinum and taxane resistant/refractory ovarian cancer",

author = "GC Jayson",

year = "2004",

language = "English",

pages = "114--119",

journal = "Gyne. Oncol",

issn = "1095-6859",

publisher = "Elsevier BV",

}